 Home > Active Ingredient News > Antitumor Therapy > Clin Cancer Res: Activity and safety of third-generation EGFR-TKI Abvertinib in the treatment of EGFR T790M+ NSCLC

Clin Cancer Res: Activity and safety of third-generation EGFR-TKI Abvertinib in the treatment of EGFR T790M+ NSCLC

 Last Update: 2021-12-04
 Source: Internet
 Author: User

Tags

sucralfate 1 mg

clopidogrel side effects

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been identified as the standard treatment for patients with non-small cell lung cancer ( NSCLC ) with EGFR mutations

NSCLC

Abvertinib (AC0010) is a third-generation EGFR-TKI preparation based on pyridine pyrimidine.

A total of 367 adult patients were recruited for the trial

Can assess the patient's best response

In Phase 1, based on pharmacokinetics, efficacy and safety, the maximum recommended dose of Abvertinib is set at 300 mg (2/day)

The maximum recommended dose of Abvertinib was set at 300 mg (2/day) and the median duration of treatment was 24.

Progression-free survival

All patients reported at least one side effect event, and 96.

All in all, the study shows that Abvertinib 300mg (2/day) has considerable clinical activity in NSCLC patients with EGFR T790M mutation, and the side effects are controllable

Abvertinib 300mg (2/day) has considerable clinical activity in NSCLC patients with EGFR T790M mutation, and the side effects are controllable.

Original source:

Zhou Qing,Wu Lin,Hu Pei et al.

A novel third generation EGFR tyrosine kinase inhibitor Abivertinib for EGFR T790M mutant Non-Small Cell Lung Cancer: a multicenter phase1 / 2 study

in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.